Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lerable

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Thrombosis Research|May 1, 1984
In vivo attempt to consume antithrombin III by i.v. injection of a thrombin-heparin mixtureJ P Soulier, D Gozin, J Lerable
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1983
[New preparation method of C1 esterase for the dosage of its plasma inhibitor]D Gozin, M P Ollier-Hartmann, J Lerable, et al.
Journal of Medical Virology|September 1, 1995
Serum anti-p24 antibody concentration has a predictive value on the decrease of CD4 lymphocyte count higher than acid-dissociated p24 antigenL Morand-Joubert, H Bludau, J Lerable, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 1, 1990
An unknown source of vitamin K1 in patients on total parenteral nutritionO Goulet, J J Lefrere, M Guillalmont, et al.
The Journal of Infectious Diseases|June 2, 1998
The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infectionJ J Lefrère, F Roudot-Thoraval, M Mariotti, et al.
The Journal of Infectious Diseases|March 9, 1999
Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected personsJ J Lefrère, F Roudot-Thoraval, L Morand-Joubert, et al.
Transfusion|May 1, 1995
Albumin batches and B19 parvovirus DNAJ J Lefrère, M Mariotti, I De la Croix, et al.
Thrombosis and Haemostasis|December 22, 1988
Coagulation assays as diagnostic markers of hepatocellular carcinomaJ J Lefrère, J Conard, P Mavier, et al.
The Journal of Infectious Diseases|February 1, 1997
Full or partial seroreversion in patients infected by hepatitis C virusJ J Lefrère, S Guiramand, F Lefrère, et al.
Blood|November 14, 1997
Natural history of GBV-C/hepatitis G virus infection through the follow-up of GBV-C/hepatitis G virus-infected blood donors and recipients studied by RNA polymerase chain reaction and anti-E2 serologyJ J Lefrère, P Loiseau, J Maury, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Thrombosis Research|May 1, 1984
In vivo attempt to consume antithrombin III by i.v. injection of a thrombin-heparin mixtureJ P Soulier, D Gozin, J Lerable
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1983
[New preparation method of C1 esterase for the dosage of its plasma inhibitor]D Gozin, M P Ollier-Hartmann, J Lerable, et al.
Journal of Medical Virology|September 1, 1995
Serum anti-p24 antibody concentration has a predictive value on the decrease of CD4 lymphocyte count higher than acid-dissociated p24 antigenL Morand-Joubert, H Bludau, J Lerable, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 1, 1990
An unknown source of vitamin K1 in patients on total parenteral nutritionO Goulet, J J Lefrere, M Guillalmont, et al.
The Journal of Infectious Diseases|June 2, 1998
The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infectionJ J Lefrère, F Roudot-Thoraval, M Mariotti, et al.
The Journal of Infectious Diseases|March 9, 1999
Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected personsJ J Lefrère, F Roudot-Thoraval, L Morand-Joubert, et al.
Transfusion|May 1, 1995
Albumin batches and B19 parvovirus DNAJ J Lefrère, M Mariotti, I De la Croix, et al.
Thrombosis and Haemostasis|December 22, 1988
Coagulation assays as diagnostic markers of hepatocellular carcinomaJ J Lefrère, J Conard, P Mavier, et al.
The Journal of Infectious Diseases|February 1, 1997
Full or partial seroreversion in patients infected by hepatitis C virusJ J Lefrère, S Guiramand, F Lefrère, et al.
Blood|November 14, 1997
Natural history of GBV-C/hepatitis G virus infection through the follow-up of GBV-C/hepatitis G virus-infected blood donors and recipients studied by RNA polymerase chain reaction and anti-E2 serologyJ J Lefrère, P Loiseau, J Maury, et al.
Pageof 2